The Virtual Biotech: A multi-agent AI framework for therapeutic discovery and development.

In a dataset of 55,984 trials, the Virtual Biotech found that drugs targeting cell-type-specific genes were 48% more likely to reach market with 32% fewer adverse events.

• Why it matters: Drug development needs integrated evidence across biological scales and modalities, but existing tools are fragmented and don’t support end-to-end decision making.
• What they did: The Virtual Biotech is a multi-agent AI framework with divisions for target discovery, safety assessment, modality selection, and clinical development, tested at three decision points.
• The result: It integrated multimodal evidence to propose a lung cancer therapeutic strategy and analyzed a terminated ulcerative colitis trial to infer potential mechanisms of failure.